A panel of protein kinase high expression is associated with postoperative recurrence in cholangiocarcinoma

BMC Cancer

Table 5 Univariate analysis of factors predicting recurrence-free and overall survival

Variable	Recurrence-free survival			Overall survival
Variable	HR	95% CI	p	HR	95% CI	p
Sex (Male vs Female)	1.159	0.856–1.569	0.340	1.132	0.837–1.532	0.422
Age (≥61 vs < 61)	1.144	0.858–1.525	0.359	1.302	0.975–1.737	0.073
Tumor location (Extra. Vs Intra.)	0.852	0.639–1.136	0.276	0.823	0.617–1.099	0.186
Histology (Others vs Papillary)	1.221	0.914–1.631	0.176	1.111	0.832–1.483	0.476
Primary tumor (T) (III/IV vs I/II)	2.474	1.811–3.378	1.2 × 10^− 8	2.520	1.853–3.426	3.7 × 10⁻⁹
Lymph nodes metastasis (N) (Yes vs No)	1.968	1.459–2.655	9.0 × 10^− 6	2.180	1.614–2.946	3.8 × 10⁻⁷
Distant metastasis (M) (Yes vs No)	1.783	0.967–3.289	0.064	2.093	1.133–3.869	0.018
TNM Stage (III/IV vs I/II)	2.387	1.738–3.278	7.6 × 10⁻⁸	2.564	1.865–3.525	6.7 × 10^− 9
EGFR (High vs Low)	1.593	1.173–2.164	0.003	1.452	1.071–1.969	0.016
HER4 (High vs Low)	1.646	1.207–2.244	0.002	1.412	1.042–1.914	0.026
EphA3 (High vs Low)	1.465	1.091–1.966	0.011	1.424	1.060–1.913	0.019
Protein panel^a (2–3 markers high vs Others^b)	1.746	1.281–2.380	4.2 × 10^− 4	1.476	1.087–2.003	0.013
Combined of protein panel and CA19–9 level (2–3 markers high and CA19–9 high vs Others^c)	2.435	1.512–3.921	2.5 × 10^− 4	1.849	1.166–2.932	0.009

TNM Size of primary tumor-node metastasis-distant metastasis, EGFR Epidermal growth factor receptor, HER Human epidermal growth factor receptor, EphA3 Erythropoietin-producing hepatocellular carcinoma receptor type-A3, Protein panel^a: the expression of EGFR, HER4 and EphA, Others^b: 0–1 marker high, Others^c: three groups of patients (0–1 marker high and CA19–9 low, 0–1 marker high and CA19–9 high or 2–3 markers high and CA19–9 low)

ISSN: 1471-2407